Uccc-Gi-20-01- Feasibility Of Total Neoadjuvant Therapy In Resectable Biliary Adenocarcinoma
Posted Date: May 6, 2021
- Investigator: Jordan Kharofa
- Specialties: Cancer, Oncology
- Type of Study: Drug
The purpose of this trial is to evaluate whether a neoadjuvant paradigm is feasible in resectable biliary adenocarcinoma. The study will use Gemcitabine/cisplatin, followed by chemoradiation.
Criteria:
Patients Must Have Either Biopsy Proven Biliary Adenocarcinoma (Intrahepatic, Hilar, Or Extrahepatic Cholangiocarcinoma), Or Gallbladder Adenocarcinoma, Ecog 0-2, Adequate Organ Function As Defined By Protocol, No Metastatic Disease
Keywords:
Biliary Cancer, Adenocarcinoma
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com